Neuromethods,
Год журнала:
2023,
Номер
unknown, С. 3 - 47
Опубликована: Янв. 1, 2023
Alzheimer's
disease
(AD)
is
a
neurological
ailment
that
affects
older
people
and
causes
steady
decline
in
their
cognitive
function.
The
impairments
found
are
presumed
to
be
the
result
of
synapse
disruption
neurochemical
deficits.
Several
abnormalities
have
been
throughout
progressive
aging,
these
connected
dysfunction
seen
sporadic
stage
AD.
There
various
hypotheses
explaining
AD,
such
as
aberrant
deposits
amyloid
β
(Aβ)
protein
extracellular
spaces
neurons,
production
twisted
fibers
tau
proteins
inside
cholinergic
neuron
damage,
inflammation,
oxidative
stress,
so
on,
many
anti-AD
therapeutics
developed
based
on
hypotheses.
While
current
pharmacological
treatments
assist
relieving
symptoms
AD
enhance
patient's
quality
life,
they
do
not
halt
or
cure
disease.
Presently,
targeted
drug
delivery
central
nervous
system
(CNS)
for
therapy
hampered
by
difficulties
posed
blood-brain
interfaces
surrounding
CNS,
reducing
therapeutic
bioavailability.
Among
innovative
ways
overcome
restrictions
successfully
deliver
pharmaceuticals
nanoparticles
(NPs)
can
barriers,
offering
new
strategies
terms
dealing
drugs
cross
barrier
(BBB)
enter
brain
more
adequately.
Various
options
treatment
shown
promising
results
preclinical
research
currently
being
tested
clinical
trials
last
decade.
In
addition
generating
chemical
entities,
natural
compounds
alkaloids,
terpenoids,
flavonoids,
curcumin
isolated
evaluated
all
demonstrated
actions
against
range
targets.
Moreover,
computational
techniques
also
proven
quite
useful
time
money
when
developing
therapies.
Molecular
modeling,
virtual
screening,
docking
widely
used
researchers
worldwide
recent
years.
These
already
aided
development
several
compounds.
purpose
this
chapter
summarize
highlight
advancements
novel
therapies
implications
Pharmaceutics,
Год журнала:
2023,
Номер
15(5), С. 1370 - 1370
Опубликована: Апрель 29, 2023
To
evaluate
the
neuroprotective
effect
of
topical
ocular
administration
fluoxetine
(FLX)
in
a
mouse
model
acute
retinal
damage.Ocular
ischemia/reperfusion
(I/R)
injury
C57BL/6J
mice
was
used
to
elicit
damage.
Mice
were
divided
into
three
groups:
control
group,
I/R
and
group
treated
with
FLX.
A
pattern
electroretinogram
(PERG)
as
sensitive
measure
ganglion
cell
(RGC)
function.
Finally,
we
analyzed
mRNA
expression
inflammatory
markers
(IL-6,
TNF-α,
Iba-1,
IL-1β,
S100β)
through
Digital
Droplet
PCR.PERG
amplitude
values
significantly
(p
<
0.05)
higher
I/R-FLX
compared
whereas
PERG
latency
reduced
I/R-FLX-treated
group.
Retinal
increased
after
injury.
FLX
treatment
able
attenuate
damage.Topical
effective
counteracting
damage
RGCs
preserving
Moreover,
attenuates
production
pro-inflammatory
molecules
elicited
by
Further
studies
need
be
performed
support
use
agent
degenerative
diseases.
The
present
article
delves
into
the
complex
correlation
among
neurotransmitter
dysregulation,
antidepressant
therapy,
and
Alzheimer’s
disease
(AD).
Progressive
cognitive
decline
neuropsychiatric
symptoms
are
outcome
of
AD,
predominant
type
dementia,
which
is
characterized
by
pathological
manifestations
β-amyloid
plaques
hyperphosphorylated
tau
tangles.
Amyloid
plaque
formation,
protein
phosphorylation,
oxidative
stress,
other
pathophysiological
processes
all
aided
dysfunctional
neurotransmitters
such
as
acetylcholine,
histamine,
gamma-aminobutyric
acid,
serotonin.
On
hand,
medications
that
treat
depression
AD
patients
turn
out
to
be
very
important.
These
include
selective
noradrenaline
reuptake
inhibitors
(SNRIs),
serotonin
(SSRIs)
atypical
antidepressants.
Depression
neurologic
disorders
correlated
in
both
directions,
supporting
this
treatment
approach.
effects
antidepressants
reducing
production
amyloid
plaque,
improving
function,
stimulating
neurogenesis,
increasing
levels
monoamine
brain-derived
neurotrophic
factor
(BDNF)
synapses.
Life,
Год журнала:
2022,
Номер
12(10), С. 1645 - 1645
Опубликована: Окт. 19, 2022
Depression
is
a
disease
with
several
molecular
mechanisms
involved,
such
as
problems
in
the
serotonergic
pathway.
This
very
complex
and
prevalent,
thus
important
to
deeply
study
aim
overcome
high
rates
of
relapse
therapeutic
failure.
In
this
study,
two
cellular
lines
were
used
(HT-22
SH-SY5Y
cells)
gain
insight
about
role
serotonin
type
3
(5-HT3)
receptor
stress
induced
by
hydrogen
peroxide
and/or
corticosterone.
research,
these
compounds
are
known
mimic
levels
oxidative
dysfunction
hypothalamus-hypophysis-adrenal
axis
action
glucocorticoids,
usually
present
depressed
individuals.
The
5-HT3
also
be
involved
depression,
previously
demonstrated
studies
that
highlight
receptors
promising
targets
for
antidepressant
therapy.
Indeed,
drugs
work
(mirtazapine,
scopolamine,
lamotrigine)
interact
receptor.
Thus,
using
cell
morphology,
viability
(neutral
red
MTT),
HPLC
assays,
aimed
understand
H2O2/corticosterone
HT-22
lines.
We
concluded
antagonism
may
attenuation
H2O2-induced
cells,
but
not
corticosterone-induced
stress.
Neuromethods,
Год журнала:
2023,
Номер
unknown, С. 3 - 47
Опубликована: Янв. 1, 2023
Alzheimer's
disease
(AD)
is
a
neurological
ailment
that
affects
older
people
and
causes
steady
decline
in
their
cognitive
function.
The
impairments
found
are
presumed
to
be
the
result
of
synapse
disruption
neurochemical
deficits.
Several
abnormalities
have
been
throughout
progressive
aging,
these
connected
dysfunction
seen
sporadic
stage
AD.
There
various
hypotheses
explaining
AD,
such
as
aberrant
deposits
amyloid
β
(Aβ)
protein
extracellular
spaces
neurons,
production
twisted
fibers
tau
proteins
inside
cholinergic
neuron
damage,
inflammation,
oxidative
stress,
so
on,
many
anti-AD
therapeutics
developed
based
on
hypotheses.
While
current
pharmacological
treatments
assist
relieving
symptoms
AD
enhance
patient's
quality
life,
they
do
not
halt
or
cure
disease.
Presently,
targeted
drug
delivery
central
nervous
system
(CNS)
for
therapy
hampered
by
difficulties
posed
blood-brain
interfaces
surrounding
CNS,
reducing
therapeutic
bioavailability.
Among
innovative
ways
overcome
restrictions
successfully
deliver
pharmaceuticals
nanoparticles
(NPs)
can
barriers,
offering
new
strategies
terms
dealing
drugs
cross
barrier
(BBB)
enter
brain
more
adequately.
Various
options
treatment
shown
promising
results
preclinical
research
currently
being
tested
clinical
trials
last
decade.
In
addition
generating
chemical
entities,
natural
compounds
alkaloids,
terpenoids,
flavonoids,
curcumin
isolated
evaluated
all
demonstrated
actions
against
range
targets.
Moreover,
computational
techniques
also
proven
quite
useful
time
money
when
developing
therapies.
Molecular
modeling,
virtual
screening,
docking
widely
used
researchers
worldwide
recent
years.
These
already
aided
development
several
compounds.
purpose
this
chapter
summarize
highlight
advancements
novel
therapies
implications
